KNSA · Kiniksa Pharmaceuticals, Ltd. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $214.27M | - | $180.85M | $156.80M | $137.78M | - | $112.21M | $108.63M | $79.86M | - |
| Cost of Revenue | $20.80M | - | $20.26M | $18.60M | $17.87M | - | $20.11M | $12.32M | $10.58M | - |
| Gross Profit | $193.47M | - | $160.60M | $138.19M | $119.92M | - | $92.11M | $96.31M | $69.28M | - |
| R&D | $27.48M | - | $24.17M | $18.75M | $19.32M | - | $26.06M | $24.02M | $26.33M | - |
| SG&A | $61.15M | - | $49.10M | $46.86M | $43.53M | - | $46.40M | $42.40M | $38.68M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $468.0K | - | $27.0K | $13.0K | $345.0K | - | $87.0K | $119.0K | $466.0K | - |
| Operating Income | $29.27M | - | $24.02M | $20.16M | $13.27M | - | ($9.66M) | ($117.0K) | ($16.54M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $10.09M | - | $8.72M | $5.04M | $7.03M | - | $5.49M | $6.21M | $3.43M | - |
| Net Income | $22.59M | - | $18.43M | $17.83M | $8.54M | - | ($12.69M) | ($3.91M) | ($17.70M) | - |
| EPS - Basic | $0.30 | - | $0.25 | $0.24 | $0.12 | - | ($0.18) | ($0.06) | ($0.25) | - |
| EPS - Diluted | $0.27 | - | $0.23 | $0.23 | $0.11 | - | ($0.18) | ($0.06) | ($0.25) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $189.95M | $165.60M | $174.86M | $192.04M | $157.13M | $183.58M | $97.38M | $99.27M | $141.08M | $107.95M |
| Accounts Receivable | $23.22M | $15.59M | $51.74M | $31.91M | $40.06M | $41.72M | $24.89M | $20.45M | $15.99M | $21.27M |
| Inventory | $73.14M | $54.90M | $41.40M | $48.18M | $22.07M | $26.36M | $28.68M | $34.86M | $27.28M | $31.12M |
| Accounts Payable | $24.40M | $2.03M | $6.15M | $8.96M | $1.98M | $2.04M | $8.33M | $7.39M | $5.63M | $8.25M |
| Current Assets | $594.17M | $527.18M | $475.53M | $420.31M | $355.91M | $331.80M | $311.30M | $301.02M | $270.59M | $276.30M |
| Total Assets | $825.28M | $763.63M | $712.33M | $661.15M | $599.33M | $580.55M | $555.30M | $542.43M | $519.67M | $526.32M |
| Current Liabilities | $156.61M | $139.18M | $123.59M | $117.83M | $97.27M | $100.62M | $95.95M | $84.29M | $64.21M | $63.67M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $219.59M | $196.03M | $176.95M | $166.14M | $141.84M | $142.12M | $118.29M | $107.33M | $87.78M | $87.48M |
| Stockholders' Equity | $605.69M | $567.61M | $535.38M | $495.01M | $457.49M | $438.44M | $437.01M | $435.10M | $431.89M | $438.84M |
| Retained Earnings | ($439.55M) | ($462.14M) | ($476.34M) | ($494.77M) | ($512.60M) | ($521.14M) | ($512.25M) | ($499.56M) | ($495.65M) | ($477.95M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $50.20M | - | - | - | $22.32M | - | - | - | $3.99M | - |
| Investing Cash Flow | ($31.92M) | - | - | - | ($51.54M) | - | - | - | $25.52M | - |
| Financing Cash Flow | $6.07M | - | - | - | $2.77M | - | - | - | $3.61M | - |
| CapEx | $161.0K | - | - | - | $99.0K | - | - | - | $84.0K | - |
| Free Cash Flow | $50.04M | - | - | - | $22.23M | - | - | - | $3.90M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 90.3% | - | 88.8% | 88.1% | 87.0% | - | 82.1% | 88.7% | 86.7% | - |
| Operating margin | 13.7% | - | 13.3% | 12.9% | 9.6% | - | -8.6% | -0.1% | -20.7% | - |
| EBITDA margin | 13.9% | - | 13.3% | 12.9% | 9.9% | - | -8.5% | 0.0% | -20.1% | - |
| Net margin | 10.5% | - | 10.2% | 11.4% | 6.2% | - | -11.3% | -3.6% | -22.2% | - |
| Free cash flow margin | 23.4% | - | - | - | 16.1% | - | - | - | 4.9% | - |
| FCF / Net income | 2.21 | - | - | - | 2.60 | - | - | - | -0.22 | - |
| R&D / Revenue | 12.8% | - | 13.4% | 12.0% | 14.0% | - | 23.2% | 22.1% | 33.0% | - |
| SG&A / Revenue | 28.5% | - | 27.2% | 29.9% | 31.6% | - | 41.3% | 39.0% | 48.4% | - |
| Effective tax rate | 30.9% | - | 32.1% | 22.1% | 45.1% | - | - | 269.6% | - | - |
| Return on assets | 2.7% | - | 2.6% | 2.7% | 1.4% | - | -2.3% | -0.7% | -3.4% | - |
| Return on equity | 3.7% | - | 3.4% | 3.6% | 1.9% | - | -2.9% | -0.9% | -4.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.79 | 3.79 | 3.85 | 3.57 | 3.66 | 3.30 | 3.24 | 3.57 | 4.21 | 4.34 |
| Quick ratio | 3.33 | 3.39 | 3.51 | 3.16 | 3.43 | 3.04 | 2.95 | 3.16 | 3.79 | 3.85 |
| Cash ratio | 1.21 | 1.19 | 1.41 | 1.63 | 1.62 | 1.82 | 1.01 | 1.18 | 2.20 | 1.70 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.36 | 1.35 | 1.33 | 1.34 | 1.31 | 1.32 | 1.27 | 1.25 | 1.20 | 1.20 |
| Liabilities / Assets | 0.27 | 0.26 | 0.25 | 0.25 | 0.24 | 0.24 | 0.21 | 0.20 | 0.17 | 0.17 |
| Efficiency | ||||||||||
| Asset turnover | 0.26 | - | 0.25 | 0.24 | 0.23 | - | 0.20 | 0.20 | 0.15 | - |
| Inventory turnover | 0.28 | - | 0.49 | 0.39 | 0.81 | - | 0.70 | 0.35 | 0.39 | - |
| Days sales outstanding | 40d | - | 104d | 74d | 106d | - | 81d | 69d | 73d | - |
| Days inventory outstanding | 1284d | - | 746d | 945d | 451d | - | 521d | 1033d | 941d | - |
| Days payable outstanding | 428d | - | 111d | 176d | 40d | - | 151d | 219d | 194d | - |
| Cash conversion cycle | 895d | - | 740d | 844d | 516d | - | 450d | 882d | 820d | - |
| Valuation | ||||||||||
| P / E | 178.3x | - | 168.8x | 120.3x | 201.9x | - | - | - | - | - |
| P / B | 6.6x | - | 5.8x | 4.4x | 3.7x | - | 4.1x | 3.0x | 3.2x | - |
| P / S | 18.5x | - | 17.2x | 13.8x | 12.3x | - | 16.0x | 12.2x | 17.5x | - |
| EV / EBITDA | 127.1x | - | 122.0x | 97.4x | 112.7x | - | - | 613192.8x | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 55.5% | - | 61.2% | 44.3% | 72.5% | - | 67.4% | 52.0% | 65.2% | - |
| Revenue CAGR (3y) | 64.3% | - | 22.2% | 79.8% | 62.4% | - | 110.1% | 141.6% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 61.3% | - | 74.4% | 43.5% | 73.1% | - | 58.9% | 44.9% | - | - |
| Operating income growth (YoY) | 120.5% | - | - | - | - | - | 11.6% | 96.3% | -47.7% | - |
| Net income growth (YoY) | 164.6% | - | - | - | - | - | 8.4% | - | -44.3% | - |
| EPS growth (YoY) | 145.5% | - | - | - | - | - | 10.0% | - | -38.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 125.1% | - | - | - | 469.4% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 32.4% | 29.5% | 22.5% | 13.8% | 5.9% | -0.1% | 7.9% | 5.7% | 10.7% | 10.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$677.56M totalPharmaceutical Segment$677.56M · 100.0%
Product / service
$677.56M totalProduct$677.56M · 100.0%
Geographic
$677.56M totalUS$676.75M · 99.9%
GB$814.0K · 0.1%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Kiniksa Pharmaceuticals against the 5 most active filers in the same SIC group.